Mycophenolate mofetil: A pharmacoeconomic review of its use in solid organ transplantation

PharmacoEconomics

Volumn 20, Issue 10, 2002, Pages 675-713

  Young, Melissa ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE DISEASE; ANEMIA; BLOOD TOXICITY; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYTOMEGALOVIRUS INFECTION; DATA BASE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ECONOMIC ASPECT; ECONOMIC EVALUATION; FOLLOW UP; FRANCE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; GRAFT FAILURE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LONG TERM EXPOSURE; META ANALYSIS; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; OUTPATIENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TIME SERIES ANALYSIS; UNITED STATES;

EID: 0036373059     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220100-00004     Document Type: Review

References (155)

1. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: Focus on immunosuppression
2. Live and then give. The facts about organ donation
3. Need, demand, and supply in kidney transplantation: A review of the data, an examination of the issues, and projections through the year 2000
4. Report card on renal transplantation
5. Improved graft survival after renal transplantation in the United States, 1988 to 1996
6. Declining influence of race on the outcome of living donor renal transplantation
7. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients
8. Limits of MMF in liver transplantation - Discontinuation of a CYA withdrawal trial
9. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients
10. Heart allograft vascular disease: An obliterative vascular disease in transplanted hearts
11. Postoperative management following heart transplantation
12. Lung transplantation
13. A prospective comparison of systemic-bladder versus portal-enteric drainage in vascularized pancreas transplantation
14. Pancreas and pancreas-kidney transplantation
15. Maintenance immunosuppression
16. Clinical application of immunosuppressive agents in renal transplantation
17. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection
18. Mycophenolate mofetil: A review of its use in the management of solid organ transplantation
19. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids
20. Does transplantation produce quality of life benefits? A quantitative analysis of the literature
21. A study of the quality of life and cost-utility of renal transplantation
22. The costs and outcome of kidney transplant graft failure
23. The quality of life of patients with end-stage renal disease
24. Changes in quality of life and working capacity before and after kidney transplantation
25. Quality of life of children post transplantation compared to children on dialysis
26. Quality of life after pancreas transplantation: A review
27. The effect of lung transplantation on health-related quality of life: A longitudinal study
28. Quality of life (QoL) change after kidney, liver and heart transplantation (OTx)
29. Clinical determinants of health related quality of life (HRQL) in solid organ transplant recipients
30. Quality of life after renal transplantation
31. Health related quality of life after heart-, kidney- and liver transplantation
32. Long-term quality of life after kidney and simultaneous pancreas-kidney transplantation
33. An economic analysis of kidney transplantation
34. Relative cost of cadaveric versus living donor kidney transplantation
35. National Association of Health Authorities and Trusts. Organ transplants
36. HLA-identity - Long-term renal graft survival, acute vascular, chronic vascular, and acute interstitial rejection
37. Hemodialysis and transplantation cost-effectiveness analysis
38. How expensive is heart transplantation (HTx) when compared with the treatment of end stage heart failure (ESHF) before HTx? A single center analysis of 350 patients
39. Cost utility analysis of liver and kidney transplantation in Germany
40. Cost-utility of lung transplantation: A pilot study
41. Cost-utility analysis of living-donor kidney transplantation followed by pancreas transplantation versus simultaneous pancreas-kidney transplantation
42. Cost-effectiveness studies of renal transplantation
43. The impact of immunosuppressive regimens on the cost of liver transplantation - Results from the U.S. FK506 Multicenter Trial
44. Costing study of liver transplantation in adults
45. An economic analysis of heart-lung transplantation: Costs, insurance coverage, and reimbursement
46. Cost analysis of kidney-pancreas and kidney-islet transplant
47. Drug use concomitant with cyclosporine immunosuppressive therapy for 3 years after renal transplantation
48. The cost of transplant graft maintenance following solid organ transplantation
49. Effects of three immunosuppressive drug protocols on cadaver renal transplantation costs after 4 years of therapy
50. A model for analyzing the cost of main clinical events after cardiac transplantation
51. A model for analyzing the cost of the main clinical events after lung transplantation
52. Lifetime costs of lung transplantation: Estimation of incremental costs
53. Economic costs of expanded criteria donors in renal transplantation
54. Economic cost of expanded criteria donors in cadaveric renal transplantation
55. Financial impact of cold ischemia time in renal transplantation
56. The impact of delayed graft function on the long-term outcome of renal transplantation
57. Economic impact of delayed graft function
58. World Congress on Transplantation tackles multi-faceted transplant challenges: Researchers focus on improving patient management and decreasing costs [press release, GTFH Public Relations]
59. The cost of rejection in liver allograft recipients
60. The economic impact of cytomegalovirus infection after liver transplantation
61. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
62. Risks and costs of end-stage renal disease after heart transplantation
63. Incidence and cost of steroid side effects after renal transplantation
64. Costs for successful vs failed kidney transplantation: A two year follow-up
65. A contemporaneous comparison of MMF and AZA in the USRDS data base
66. The use of mycophenolate mofetil in transplant recipients
67. Mycophenolate mofetil as induction therapy after liver transplantation
68. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
69. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results
70. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial
71. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
72. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation
73. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
74. Mycophenolate mofetil in cadaveric renal transplantation
75. Mycophenolate-update after it has come of age
76. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection
77. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: Four years of experience
78. Maintenance immunosuppression: New agents and persistent dilemmas
79. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil
80. One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation
81. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation
82. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation
83. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: A six-month analysis
84. Mycophenolate mofetil/Neoral/steroid vs Neoral/steroid therapy for prophylaxis of acute rejection in renal transplant recipients
85. Mycophenolate mofetil usage, in renal transplant recipients
86. Improvement of kidney graft survival replacing azathioprine by mycophenolate mofetil in induction regimen
87. Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation
88. Cost considerations and the use of mycophenolate mofetil in renal transplantation
89. Improved primary transplant success rates using a triple regimen of cyclosporine microemulsion, mycophenolate mofetil and prednisone
90. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations
91. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients
92. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients
93. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients
94. Steroid withdrawal in renal transplant recipients
95. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients
96. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
97. 3 Year follow-up of randomized multicenter kidney transplant study comparing tacrolimus (TAC) + azathioprine (AZA) vs cyclosporine modified (CSA) + mycophenolate mofetil (MMF) vs TAC+MMF
98. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: Results at 2 years
99. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection
100. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: Three-year follow-up
101. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection
102. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
103. Outcome of anti-calcineurin-free renal transplantation in recipients with marginal donors
104. Selective Cellcept therapy in high-risk renal transplant recipients
105. Mycophenolate mofetil compared to azathioprine improves survival in patients surviving the initial cardiac transplant hospitalization: An analysis of the joint UNOS/ISHLT thoracic registry
106. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels
107. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring
108. Acute cardiac ongoing rejection: Comparison between different strategies
109. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients
110. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation
111. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: Complete report on 350 primary adult liver transplantations
112. One year analysis of an ongoing international randomized study of mycophenolate mofetil vs azathioprine in lung transplantation
113. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil vs azathioprine in the prevention of acute lung allograft rejection
114. Effect of reducing cyclosporine dose by 50% in stable renal transplant recipients in the mycophenolate (MMF) era: A randomized controlled trial
115. Chronic allograft nephropathy: Prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution
116. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction
117. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen
118. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation?
119. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study
120. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients
121. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - A prospective randomized study
122. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection
123. Mycophenolate mofetil-treated primary renal transplant patients can successfully undergo steroid withdrawal under cyclosporine or tacrolimus regimens
124. Outcome of renal transplantation (TX) in pediatric patients (PTS) treated with mycophenolate mofetil (MMF)
125. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation
126. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management
127. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients
128. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: Is it necessary?
129. Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation
130. Mycophenolate mofetil does not lower the incidence or cost of rejection, use of OKT3, or improve survival after liver transplantation and rapid (14D) steroid withdrawal
131. Cost-effectiveness analysis of mycophenolate mofetil treatment for intractable acute rejection in renal transplantation recipients
132. The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation
133. Economic contribution of prophylactic immunosuppressive therapy with mofetil mycofenolate in renal cadaveric transplant recipients
134. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation
135. Mycophenolate mofetil - Is it worth the cost? The in-favor opinion
136. Cost savings for lifetime immunosuppression from MMF in cadaveric renal transplant
137. The cost-effectiveness of immunosuppression therapy after renal transplantation
138. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant
139. Tacrolimus and mycophenolate mofetil in high-risk kidney patients
140. Mycophenolate mofetil monotherapy: An example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients
141. Withdrawal of mycophenolate mofetil in stable renal transplant recipients
142. Withdrawal of mycophenolate mofetil in stable renal transplant recipients
143. A one-center experience with a short course of mycophenolic acid
144. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone
145. Provocative effects of the immunosuppressants rapamycin, tacrolimus, and dexamethasone on Pneumocystis carinii pneumonitis in contrast to the anti-Pneumocystis carinii pneumonitis effects of mycophenolate mofetil
146. Racial differences in clinical outcome using tacrolimus and mycophenolate mofetil immunosuppression in heart transplantation
147. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients
148. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function
149. Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors
150. Preliminary experience with tacrolimus and mycophenolate mofetil in high risk renal transplant recipients
151. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft